HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Integrative medicine for oncology requires ‘educated, evidence-based approach’


Should hem/oncs recommend integrative therapies to their patients?


Conflict management and data integrity in the shadows

John Sweetenham, MD


Neoadjuvant therapy provides opportunity to discover new treatment strategies

Douglas Yee, MD

Guest Commentary

Moving forward: HPV vaccination is only the beginning


New biomarkers and therapeutic target discoveries in molecular oncology

Wafik S. El-Deiry, MD, PhD, FACP

Community health worker intervention may benefit adolescents with sickle cell disease

Meeting News

Women, older patients with sarcoma more likely to use complementary medicine

Drug vial optimization reduces waste, saves costs

Oncology pharmacy navigators guide patients to reduce costs, improve treatment compliance

Tools aid in detection, treatment of cancer-related cognitive impairment

Pembrolizumab plus chemotherapy prolongs OS, PFS for metastatic lung cancer

Atezolizumab plus chemotherapy improves small cell lung cancer survival

LOXO-292 induces durable benefit in RET-altered thyroid cancer

BLU-667 active in RET-altered thyroid cancer

Journalist, breast cancer survivor Joan Lunden to speak at Hematology/Oncology Pharmacy Association conference

Thyroid cancer registry helps predict tumor persistence, recurrence in urban populations

Pathologist pioneered program that allows patients to see ‘the dragon’ they are trying to ‘slay’

ACCC presents Otis W. Brawley, MD, its prestigious Achievement Award

Partnership aims to bring early-phase trials to more patients

Multistrain probiotic may reduce mild, moderate chemotherapy-induced diarrhea

ESMO honors several oncology leaders

Post-hoc analysis supports pembrolizumab’s benefit in recurrent head, neck squamous cell carcinoma

Biden Community Cancer Summit unites physicians, advocates fighting for ‘urgency of now’

In the Journals Plus

Ruxolitinib-azacytidine combination shows ‘synergistic efficacy’ for myelofibrosis

Lenalidomide ‘best maintenance option’ for multiple myeloma

4L lymph node dissection may improve lung cancer survival

Men whose brothers have aggressive prostate cancer at increased risk

Rare Hodgkin lymphoma subtype has good prognosis after relapse

Weight-adjusted tinzaparin provides safe thromboprophylaxis after bariatric surgery

FDA News

FDA approves once-weekly Kyprolis for relapsed, refractory multiple myeloma

FDA awards $18 million to fund trials of medical products for rare diseases

FDA grants breakthrough therapy designation to Rubraca for prostate cancer

FDA approves Vizimpro for EGFR-mutated non-small cell lung cancer

Three community oncology practices join forces to ‘transform’ cancer care delivery

Association of Pediatric Hematology/Oncology Nurses presents several awards

Lung cancer specialist joins Perlmutter Cancer Center

CAR T-cell therapy appears safe for multiple myeloma

Adcetris improves PFS in CD30-expressing peripheral T-cell lymphoma